title: Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?
abstract: The possible effects of sildenafil citrate administration at therapeutic dosage on visual acuity, color vision, intraocular pressure, macular thickness, macular volume, and central serous chorioretinopathy in patients with erectile dysfunction were evaluated. The study consisted of 43 male patients diagnosed as having erectile dysfunction according to the first five question version of International Index of Erectile Function (IIEF-5). All patients were given sildenafil citrate 50 mg po 2 to 3 times/week for a month. The patients were evaluated at the first week and at the end of the treatment. The macular thickness and volume assessments with optic coherence tomography did not differ significantly in foveal, parafoveal areas, parafoveal superior hemisphere, parafoveal inferior hemisphere, parafoveal temporal, superior, nasal, and inferior quadrants. Central serous chorioretinopathy was not found in any of the patients.
authors.affiliation: Ministry of Health, Ankara Ataturk Research and Training Hospital, Department of Ophthalmology, Ankara, Turkey.
authors.forename: Elif
authors.initials: E
authors.lastname: Damar
authors.forename: Yasin
authors.initials: Y
authors.lastname: Toklu
authors.forename: Altug
authors.initials: A
authors.lastname: Tuncel
authors.forename: Melih
authors.initials: M
authors.lastname: Balci
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Aslan
authors.forename: Saban
authors.initials: S
authors.lastname: Simsek
authors.forename: Ali
authors.initials: A
authors.lastname: Atan
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate
keywords: erectile dysfunction; sexual health